Attached files

     BOARD OF DIRECTORS APPOINTS CHARLES KUMMETH AS CHIEF EXECUTIVE
                OFFICER AND DIRECTOR OF TECHNE CORPORATION

Minneapolis, Minnesota - March 18, 2013 - The Board of Directors of Techne
Corporation announced today that Charles Kummeth has been appointed as the
Company's Chief Executive Officer and a director of the Company, effective
upon the commencement of his employment, which is expected to be April 1,
2013. Gregory J. Melsen, who has served as the Company's interim CEO since
November 2012, will continue to serve as Vice President of Finance and Chief
Financial Officer of the Company.

Mr. Kummeth has served as President of Mass Spectrometry and Chromatography
at Thermo Fisher Scientific Inc. from September 2011. He was President of the
company's Laboratory Consumables Division from 2009 to September 2011.  At
Thermo Fisher Scientific, Mr. Kummeth led a team of thousands of employees to
over a billion dollars in annual sales.  Prior to joining Thermo Fisher, Mr.
Kummeth served in various roles at 3M Corporation, most recently as the Vice
President of the company's Medical Division from 2006 to 2008.

"We are very pleased to welcome Chuck as Techne's new CEO," commented Robert
Baumgartner, Chairman of Techne's Board of Directors.  "Chuck joins us with a
tremendous executive track record of success and major accomplishments
working for a range of businesses, including two Fortune 500 companies, and
was directly responsible for driving growth for numerous multi-billion dollar
businesses.  He has global, successful P&L experience with extensive
experience with mergers, acquisition integration, operations and deep
international experience.  Chuck has a warm personality and a natural
instinct for leading teams and growing businesses."

Mr. Baumgartner continued, "We are also pleased to report Chuck knows
Minneapolis and our local business community very well as he currently lives
in the Minneapolis area and spent years here in post-graduate studies.  As we
transition to our new executive leadership, we want to thank Greg Melsen for
his extraordinary efforts and leadership as interim CEO during the
process.  Greg has been a dedicated and effective leader managing this
transition process and will continue in his key executive role as Vice
President of Finance and CFO.  Techne has a strong business with an excellent
reputation that generates significant annual cash-flows.  We are excited to
focus on the next chapter of growth and opportunity for Techne under Chuck's
leadership."

Mr. Kummeth stated, "I am extremely excited about joining Techne as their
CEO. Techne has a strong legacy for innovation, quality and brand, all the
components necessary to be successful in today's highly competitive but
rapidly growing life science research markets. I look forward to leading the
organization as Techne expands globally, particularly in Asia and emerging
markets."

About Techne Corporation
Techne Corporation has two operating subsidiaries:  Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe,
Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty
manufacturer of biological products.  R&D Systems has three operating
subsidiaries, BiosPacific, Inc. (BiosPacific), located in Emeryville,
California, Boston Biochem, Inc., located in Cambridge, Massachusetts and R&D
Systems China Co. Ltd., (R&D China), located in Shanghai, China. BiosPacific
is a worldwide supplier of biologics to manufacturers of in vitro diagnostic
systems and immunodiagnostic kits. Boston Biochem is a leading developer of
ubiquitin-related research products. R&D China and R&D Europe distribute
biotechnology products.  R&D Europe has two subsidiaries, Tocris Holding, Ltd
(Tocris) of Bristol, England and R&D Systems GmbH, a German sales operation.
Tocris is a leading supplier of reagents for non-clinical life science
research. Further information about the Company can be found at www.techne-
corp.com.


Forward-Looking Statements
Certain statements found in this release may constitute forward-looking
statements as defined in the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect the speaker's current views with
respect to future events and financial performance and include any statement
that does not directly relate to a current or historical fact. Forward-
looking statements can generally be identified by the words "believe,"
"expect," "anticipate" or "intend" or similar words.  The following important
factors, among others, have affected and, in the future, could affect the
Company's actual results: the integration of new leadership, the introduction
and acceptance of new biotechnology and hematology products, implementation
and execution of global expansion plans, the levels and particular directions
of research by the Company's customers, the impact of the growing number of
producers of biotechnology research products and related price competition,
general economic conditions, the impact of currency exchange rate
fluctuations, and the costs and results of research and product development
efforts of the Company and of companies in which the Company has invested or
with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled
"Risk Factors" in the Company's annual report on Form 10-K and quarterly
reports on Form 10-Q as filed with the Securities and Exchange Commission. We
undertake no obligation to update or revise any forward-looking statements we
make in our press releases due to new information or future events. Investors
are cautioned not to place undue emphasis on these statements.



Contact
Gregory J. Melsen
Interim Chief Executive Officer and Chief Financial Officer
Techne Corporation
(612) 379-8854